Title : Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients.

Pub. Date : 2021 Aug

PMID : 33649523






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The heterozygous genotype of CYP3A4*22 showed a trend of association with skin reactions in pts treated with paclitaxel and nab-paclitaxel (RR = 6.92; 95% CI 0.47, 99.8; p = 0.0766). Paclitaxel cytochrome P450 family 3 subfamily A member 4 Homo sapiens
2 The heterozygous genotype of CYP3A4*22 showed a trend of association with skin reactions in pts treated with paclitaxel and nab-paclitaxel (RR = 6.92; 95% CI 0.47, 99.8; p = 0.0766). Paclitaxel cytochrome P450 family 3 subfamily A member 4 Homo sapiens
3 Despite the population was heterogeneous, CYP3A4*22 and CYP2C8 SNPs may influence paclitaxel and nab-paclitaxel toxicity and ABCB1 c.3435 may affect taxanes effectiveness, even if any statistically significant was found. Paclitaxel cytochrome P450 family 3 subfamily A member 4 Homo sapiens
4 Despite the population was heterogeneous, CYP3A4*22 and CYP2C8 SNPs may influence paclitaxel and nab-paclitaxel toxicity and ABCB1 c.3435 may affect taxanes effectiveness, even if any statistically significant was found. Paclitaxel cytochrome P450 family 3 subfamily A member 4 Homo sapiens